Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 25

1.

Valbenazine: First Global Approval.

Kim ES.

Drugs. 2017 Jul;77(10):1123-1129. doi: 10.1007/s40265-017-0770-9. Review.

PMID:
28578484
2.

Investigational drugs in Phase I and Phase II for Levodopa-induced dyskinesias.

Cerri S, Siani F, Blandini F.

Expert Opin Investig Drugs. 2017 Jul;26(7):777-791. doi: 10.1080/13543784.2017.1333598. Epub 2017 Jun 1. Review.

PMID:
28535734
3.

Efficient Trial Design - FDA Approval of Valbenazine for Tardive Dyskinesia.

Davis MC, Miller BJ, Kalsi JK, Birkner T, Mathis MV.

N Engl J Med. 2017 Jun 29;376(26):2503-2506. doi: 10.1056/NEJMp1704898. Epub 2017 May 10. No abstract available.

PMID:
28489481
4.

Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.

Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE.

Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960. Epub 2017 Apr 26.

5.

Deutetrabenazine: Treatment of hyperkinetic aspects of Huntington's disease, tardive dyskinesia and Tourette syndrome.

Paton DM.

Drugs Today (Barc). 2017 Feb;53(2):89-102. doi: 10.1358/dot.2017.53.2.2589164. Review.

PMID:
28387387
6.

KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.

Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang GS, O'Brien CF.

Am J Psychiatry. 2017 May 1;174(5):476-484. doi: 10.1176/appi.ajp.2017.16091037. Epub 2017 Mar 21.

PMID:
28320223
7.

Valbenazine for the treatment of tardive dyskinesia.

Barquero N.

Drugs Today (Barc). 2016 Dec;52(12):665-672. doi: 10.1358/dot.2016.52.12.2570977. Review.

PMID:
28276538
8.

Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update.

Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, Obeso J, Bezard E, Fernagut PO.

Lancet Neurol. 2017 Mar;16(3):238-250. doi: 10.1016/S1474-4422(17)30004-2. Epub 2017 Feb 15. Review.

PMID:
28229895
9.

Effect of Antipsychotic Type and Dose Changes on Tardive Dyskinesia and Parkinsonism Severity in Patients With a Serious Mental Illness: The Curaçao Extrapyramidal Syndromes Study XII.

Mentzel CL, Bakker PR, van Os J, Drukker M, Matroos GE, Hoek HW, Tijssen MA, van Harten PN.

J Clin Psychiatry. 2017 Mar;78(3):e279-e285. doi: 10.4088/JCP.16m11049.

PMID:
28199071
10.

Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis.

Carbon M, Hsieh CH, Kane JM, Correll CU.

J Clin Psychiatry. 2017 Mar;78(3):e264-e278. doi: 10.4088/JCP.16r10832.

PMID:
28146614
11.

High Incidence and Prevalence of Drug-Related Movement Disorders in Young Patients With Psychotic Disorders.

Mentzel TQ, Lieverse R, Bloemen O, Viechtbauer W, van Harten PN; Genetic Risk and Outcome of Psychosis (GROUP) Investigators.

J Clin Psychopharmacol. 2017 Apr;37(2):231-238. doi: 10.1097/JCP.0000000000000666.

PMID:
28141621
12.

Forgotten but not gone: new developments in the understanding and treatment of tardive dyskinesia.

Meyer JM.

CNS Spectr. 2016 Dec;21(S1):13-24. doi: 10.1017/S1092852916000730. Review.

PMID:
28044943
13.

The Relationship Between Early Haloperidol Response and Associated Extrapyramidal Side Effects.

Rasmussen SA, Rosebush PI, Mazurek MF.

J Clin Psychopharmacol. 2017 Feb;37(1):8-12. doi: 10.1097/JCP.0000000000000637.

PMID:
28027109
14.

Citalopram-induced dyskinesia of the tongue: a video presentation.

Gaanderse M, Kliffen J, Linssen W.

BMJ Case Rep. 2016 Dec 23;2016. pii: bcr2016216126. doi: 10.1136/bcr-2016-216126.

PMID:
28011457
15.

Movement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole.

Selfani K, Soland VL, Chouinard S, Huot P.

Neurologist. 2017 Jan;22(1):24-28. doi: 10.1097/NRL.0000000000000096.

PMID:
28009769
16.
17.

Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.

Mischoulon D, Shelton RC, Baer L, Bobo WV, Curren L, Fava M, Papakostas GI.

J Clin Psychiatry. 2017 Apr;78(4):449-455. doi: 10.4088/JCP.15m10426.

PMID:
27835715
18.

Recurrent and Alternating Pisa Syndrome: A Surprising Entity.

Sáenz-Farret M, Pellene A, Micheli F.

Clin Neuropharmacol. 2016 Nov/Dec;39(6):337. No abstract available.

PMID:
27828814
19.

Peony-Glycyrrhiza Decoction for Antipsychotic-Related Hyperprolactinemia in Women With Schizophrenia: A Randomized Controlled Trial.

Man SC, Li XB, Wang HH, Yuan HN, Wang HN, Zhang RG, Tan QR, Wong HK, McAlonan GM, Wang CY, Zhang ZJ.

J Clin Psychopharmacol. 2016 Dec;36(6):572-579.

PMID:
27755159
20.

Covert Dyskinesia With Aripiprazole: A Case Report.

Mahgoub Y, Hameed A, Francis A.

Prim Care Companion CNS Disord. 2016 Jun 9;18(3). doi: 10.4088/PCC.15l01889. eCollection 2016. No abstract available.

Supplemental Content

Loading ...
Support Center